Rahul Aggarwal
Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.
Medical oncologist leading UCSF's early-phase and prostate cancer clinical research. Defined treatment-emergent small-cell neuroendocrine prostate cancer and leads PSMA radioligand and combination trials.
Pages like this
not linked directly; found by shared links- PersonThomas A. Hope
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- CompanyClarity Pharmaceuticals
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonEric J. Small
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Androgen receptor, Prostate cancer.
- PersonMichael J. Morris
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- ProductGallium-68 gozetotide (PSMA-11)
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Prostate cancer.
- PersonShahneen Sandhu
Shares Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters), Prostate cancer.